# Development of an AAV bioproduction technological platform in microalgae

M Esnard, Stéphanie Bolik, C. Audrain, A. Roblin, M. Renaudier, Jeremy

Pruvost, Luc Marchal, Oumeya Adjali

► To cite this version:

M Esnard, Stéphanie Bolik, C. Audrain, A. Roblin, M. Renaudier, et al., Development of an AAV bioproduction technological platform in microalgae. Société française de thérapie cellulaire et génique (SFTCG), Els Verhoeyen, May 2024, Nantes (Cité des Congrès), France. hal-05088504

HAL Id: hal-05088504

https://hal.science/hal-05088504v1

Submitted on 28 May 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
Development of an AAV bioproduction technological platform in microalgae

M.Esnard¹,² ; S. Bolik¹ ; C. Audrain¹ ; A. Roblin¹ ; M. Renaudie² ; J. Pruvost² ; L. Marchal² ; O. Adjali¹

¹ Laboratory TaRGeT, UMR1089 INSERM, Nantes, 44200, France.

² Laboratory GEPEA, UMR6144 CNRS, Saint-Nazaire, 44600, France.

Recombinant adeno-associated viral vectors (rAAV) are vehicles of choice for in vivo gene therapy approaches. The success of clinical trials using rAAV for the treatment of rare genetic diseases has led to the commercialization of already six rAAV-based next-generation therapies capable of treating the genetic cause of many previously incurable pathologies. Today's scientific advances make it possible to treat more complex diseases using systemic routes of administration, for which the necessary doses of rAAV are increasingly important. The field of rAAV manufacturing is thus facing new challenges: producing quality viral vectors, in large quantity and at reduced cost. Existing technologies for rAAV manufacturing are effective, but remain extremely costly when the product achieves the commercial scale because of the need of highly complex culture media. Microalgae are eukaryotic organisms that can produce bioproducts in the presence of minimal requirement (light and simple media). Microalgae large scale culture system in bioreactors are already applied on an industrial scale for the production of recombinant proteins. The GREEN-AAV project (under the national initiative Grand défi Bioproduction) is an ambitious and innovative project aiming at the evaluation of the feasibility and potential of a new microalgae cellular platform for rAAV manufacturing.